Boston Scientific re-enters neurovascular market with USD14.5B Penumbra deal

USA—Boston Scientific has announced its intention to acquire medtech firm Penumbra in a deal valued at USD14.5 billion, marking the Massachusetts-based company’s largest acquisition in two decades.

The move represents a strategic expansion of Boston Scientific’s cardiovascular device portfolio and signals the company’s return to the neurovascular market after more than a decade of absence.

The acquisition stands as the first major healthcare deal of 2026, arriving at a time when analysts and industry insiders anticipate a wave of mega-mergers throughout the year.

Companies across the healthcare sector appear poised to capitalize on a more favorable regulatory environment and easing interest rates as they seek to strengthen their market positions and expand their product offerings.

Boston Scientific CEO Mike Mahoney described the transaction as a “home run” and “financially compelling” during a conference call with analysts.

The company recently raised its annual profit forecast based on strong demand for its heart devices, and executives believe the addition of Penumbra’s products will help improve both revenue and margins over time.

The deal brings Boston Scientific back into several rapidly growing markets while filling a significant gap in the company’s neurovascular portfolio, according to Truist analyst Richard Newitter.

Boston Scientific had previously divested its neurovascular business to Stryker more than a decade ago.

Mahoney explained that the company had long viewed neurovascular as an attractive segment but wanted to enter with a scaled commercial platform and a robust pipeline.

He emphasized that entering the business required a leading portfolio, which Penumbra provides.

Medtech firms have been actively expanding their cardiovascular franchises through both internal research and development efforts and strategic acquisitions.

This trend reflects growing demand driven by an aging population and rising prevalence of heart conditions.

Last year, U.S.-based Stryker signed a USD4.9 billion deal to acquire Inari Medical, building out its portfolio of devices to treat vascular diseases.

The acquisition will give Boston Scientific access to Penumbra’s comprehensive portfolio, which includes differentiated devices designed to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack, and aneurysms.

Penumbra, headquartered in California, expects to generate approximately USD1.4 billion in sales during 2025.

Under the terms of the agreement, the deal values Penumbra at USD374 per share, representing a premium of about 19.3% over its last closing price.

Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.

Market reaction to the announcement showed contrasting movements between the two companies.

Shares of Penumbra surged over 12% to USD352.05 following the news, while Boston Scientific shares declined 4% to USD89.99.

JP Morgan analysts noted that the buyout makes a good deal of sense for Boston Scientific and could help accelerate and sustain organic revenue growth trajectory in 2027 and beyond, though they cautioned the deal may attract significant investor scrutiny.

Boston Scientific made several smaller acquisitions last year, including purchasing the remaining stake in privately held Nalu Medical to strengthen its pain-management business and acquiring Bolt Medical to bolster its cardiac pipeline.

The company expects the Penumbra transaction to close in 2026, at which point Penumbra’s chairman and chief executive officer, Adam Elsesser, will join Boston Scientific’s board of directors.